{"paper_id":"179d84b0-27eb-4984-b11a-435cfde5a7d0","body_text":"Abstract\nObjective\nTo evaluate the effect of resveratrol on an experimentally induced endometriosis rat model.\nStudy design\nAfter endometriotic implants were surgically formed, rats were randomly divided into 2 groups as control group (saline treated, n = 6) and resveratrol group (10 mg/kg/d, n = 6). The inflammatory markers and histopathological changes were assessed at the end of the treatment period.\nResults\nOur results showed (1) significant reduction in the implant size (P < .0005); (2) significantly decreased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid and plasma (P < .005); and monocyte chemotactic protein 1 (MCP-1) in the peritoneal fluid (P < .05), (3) highly significant suppression of VEGF expression in the endometriotic tissue (P < .0005); and (4) considerable histological changes in the endometriotic foci following resveratrol treatment.\nConclusion\nResveratrol appears to be effective on the development of endometriosis through its antiangiogenic and anti-inflammatory properties. Future studies with different doses of resveratrol might provide more comprehensive results regarding the treatment of endometriosis.\nSimilar content being viewed by others\nReferences\nOral E, Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am. 1997;24(2):219–233.\nGoldman MB, Cramer DW. The epidemiology of endometriosis. Prog Clin Biol Res. 1990;323:15–31.\nVinatier D, Dufour P. Is endometriosis an immunological disease? Contracept Fertil Sex. 1997;25(3):179–191.\nIborra A, Palacio JR, Ulcova-Gallova Z, Martínez P. Autoimmune response in women with endometriosis. Am J Reprod Immunol. 2000;44(4):236–241.\nNothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76(2):223–231.\nVan Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril. 2002;77(5): 861–870.\nSasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann NY Acad Sci. 2008;1127:106–115.\nTaylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011;18(9):814–823.\nYu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012;113(3):752–759.\nMarkus MA, Morris BJ. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging. 2008; 3(2):331–339.\nZhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 1999;6(2): 79–84.\nMiura T, Muraoka S, Ikeda N, Watanabe M, Fujimoto Y. Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol. 2000;86(5):203–208.\nChen CJ, Yu W, Fu YC, Wang X, Li JL, Wang W. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun. 2009;378(3):389–393.\nKang OH, Jang HJ, Chae HS, et al. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol Res. 2009;59(5):330–337.\nCsaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11(6):R165.\nVernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5):684–694.\nGüney M, Oral B, Karahan N, Mungan T. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril. 2008;89(4):934–942.\nBusquets S, Ametller E, Fuster G, et al. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 2007;245(1–2):144–148.\nKeenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 1999;72(1):135–141.\nHarrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab. 1995;80(6):1853–1858.\nBruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84(1):106–112.\nKundu JK, Shin YK, Kim SH, Surh YJ. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking kappaB kinase activity. Carcinogenesis. 2006;27(7):1465–1474.\nKumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun. 2010; 394(2):360–365.\nMcLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000;6(1):45–55.\nMahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin 6 in peritoneal fluid of women with endometriosis. Fertil Steril. 2000;73(1):166–170.\nKupker W, Schultze-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update. 2000;4(5):719–723.\nD’Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol. 2000;48(2):81–98.\nIwabe T, Harada T, Tsudo T, et al. Tumor necrosis factor-alpha promotes proliferation of endometriotic stromal cells by inducing interleukin 8 gene and protein expression. J Clin Endocrinol Metab. 2000;85(2):824–829.\nKang L, Heng W, Yuan A, Baolin L, Fang H. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: relative to inhibition of inflammatory responses. Biochimie. 2010;92(7):789–796.\nGazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction. 2002;123(2):217–226.\nArici A, Oral E, Attar E, Tazuke SI, Olive DL. Monocyte chemotactic protein-1 concentration in peritoneal fluid in patients with endometriosis and its modulation in human mesothelial cells. Fertil Steril. 1997;67(6):1065–1072.\nUlukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, Zheng W, Arici A. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril. 2009;91(3):687–693.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nErgenoÄŸlu, A.M., Yeniel, A.Ã., ErbaÅŸ, O. et al. Regression of Endometrial Implants by Resveratrol in an Experimentally Induced Endometriosis Model in Rats. Reprod. Sci. 20, 1230–1236 (2013). https://doi.org/10.1177/1933719113483014\nPublished:\nIssue date:\nDOI: https://doi.org/10.1177/1933719113483014","source_license":"CC0","license_restricted":false}